DGAP-News: MOLOGEN AG quarterly report: Both clinical studies progressing well
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Quarter Results
MOLOGEN AG quarterly report: Both clinical studies progressing well
14.11.2011 / 07:59
---------------------------------------------------------------------
- Economic development running according to plan
Berlin, November 14, 2011 - For MOLOGEN AG, the third quarter of 2011 was
characterized by the two running clinical studies. First very positive
results from the phase I/II clinical study of renal cancer medication
MGN1601 were announced. The investigators determined very good safety and
tolerability of the preparation with the patients. Furthermore, first very
promising efficacy data was collected.
Progressing in parallel was the ongoing pivotal phase II/III study with
colorectal cancer medication MGN1703. This is the furthest-developed
product in the MOLOGEN pipeline. With this, an interim analysis is
scheduled to commence at the end of the year, after the completion of which
first comments will be possible on achievement of the objectives of this
study.
Dr. Matthias Schroff, Chief Executive Officer at MOLOGEN AG: 'The first
results of the renal cancer study again confirm that with MGN1601 we have
another highly effective and tolerable drug candidate. And our colorectal
cancer medicine is progressing further in the clinical study. With regard
to the interim analysis that will begin this year, we anticipate that in
2012 we will be able to conclude a first licensing contract with a partner
from the pharmaceutical industry.
Economic development running according to plan
In the first nine months of the business year 2011, MOLOGEN's sales revenue
of about 0.7 million Euro was at the expected low preceding year's figure.
Since higher grants were accrued in the first three quarters than in the
comparison period of the previous year, at almost 0.5 million Euro other
operating profit was substantially higher than the comparison figure. The
ongoing clinical studies increased expenditure for research and development
in the first nine months of 2011 to 4.0 million Euro. With this,
expenditure was about 0.8 million Euro above the previous year's comparison
figure. This was primarily due to the increased material and personnel
expenses. In all, losses in the reporting period from January to September
2011 were 5.0 million Euro against 4.5 million Euro in the previous year.
Revenue amounting to about 10 million Euro from the capital increase
undertaken in January will financially secure the business activities of
the company until far into 2012.
Download the complete financial report: www.mologen.com.
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin
specializes in the research and development of innovative medications on
the basis of DNA structures. The activities focus on numerous product
developments which are relevant to the immune system; on the one hand
vaccines against infectious diseases and on the other hand cancer
medications. MOLOGEN AG is globally one of the few biotechnology companies
with well tolerated DNA-based cancer treatment in the clinical development
phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange (ISIN DE0006637200).
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher(at)kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation..
End of Corporate News
---------------------------------------------------------------------
14.11.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
146061 14.11.2011
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2011 - 07:59 Uhr
Sprache: Deutsch
News-ID 87172
Anzahl Zeichen: 8190
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 348 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG quarterly report: Both clinical studies progressing well"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
